Podcasts about clinical trials

  • 2,389PODCASTS
  • 8,606EPISODES
  • 32mAVG DURATION
  • 2DAILY NEW EPISODES
  • Aug 19, 2025LATEST
clinical trials

POPULARITY

20172018201920202021202220232024

Categories



Best podcasts about clinical trials

Show all podcasts related to clinical trials

Latest podcast episodes about clinical trials

OffScrip with Matthew Zachary
LEAD EP3: Fraying at the Edges

OffScrip with Matthew Zachary

Play Episode Listen Later Aug 19, 2025 22:32


The effects of the neurotoxin are taking their toll on Cooper as Shannon desperately tries to navigate the severity of their new reality.LEAD how this story ends is up to us is a true story written and produced by Shannon Burkett. Co-produced by Jenny Maguire. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett.E43 features Jenny Maguire, JD Mollison, Laith Nakli, Deirdre O'Connell, Carolyn Baeumler, Zach Shaffer, and Monique Woodley. Casting by Alaine Alldaffer and Lisa Donadio. Music by Peter Salett. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The Incubator
#341 - [Journal Club Shorts] -

The Incubator

Play Episode Listen Later Aug 17, 2025 16:00


Send us a textWhole-Body Hypothermia for Neonatal Encephalopathy in Preterm Infants 33 to 35 Weeks' Gestation: A Randomized Clinical Trial.Faix RG, Laptook AR, Shankaran S, Eggleston B, Chowdhury D, Heyne RJ, Das A, Pedroza C, Tyson JE, Wusthoff C, Bonifacio SL, Sánchez PJ, Yoder BA, Laughon MM, Vasil DM, Van Meurs KP, Crawford MM, Higgins RD, Poindexter BB, Colaizy TT, Hamrick SEG, Chalak LF, Ohls RK, Hartley-McAndrew ME, Dysart K, D'Angio CT, Guillet R, Kicklighter SD, Carlo WA, Sokol GM, DeMauro SB, Hibbs AM, Cotten CM, Merhar SL, Bapat RV, Harmon HM, Sewell E, Winter S, Natarajan G, Mosquera R, Hintz SR, Maitre NL, Benninger KL, Peralta-Carcelen M, Hines AC, Duncan AF, Wilson-Costello DE, Trembath A, Malcolm WF, Walsh MC; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network.JAMA Pediatr. 2025 Apr 1;179(4):396-406. doi: 10.1001/jamapediatrics.2024.6613.PMID: 39992674 Free PMC article. Clinical Trial.EBNEO Commentary: Is Therapeutic Hypothermia Beneficial to Infants Born Between 33 and 35 Weeks Gestation?Spahic H, Zoubovsky SP, Dietz RM.Acta Paediatr. 2025 Jul;114(7):1742-1743. doi: 10.1111/apa.70098. Epub 2025 Apr 18.PMID: 40251839 No abstract available.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

The Incubator
#341 - [Journal Club Shorts] -

The Incubator

Play Episode Listen Later Aug 17, 2025 13:42


Send us a textEarly Neurodevelopment of Extremely Preterm Infants Administered Autologous Cord Blood Cell Therapy: Secondary Analysis of a Nonrandomized Clinical Trial.Zhou L, Razak A, McDonald CA, Yawno T, McHugh DT, Whiteley G, Connelly K, Sackett V, Miller SL, Jenkin G, Novak I, Hunt RW, Malhotra A.JAMA Netw Open. 2025 Jul 1;8(7):e2521158. doi: 10.1001/jamanetworkopen.2025.21158.PMID: 40608334 Free PMC article. Clinical Trial.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Molecule to Market: Inside the outsourcing space
30 years on the rollercoaster of clinical trials

Molecule to Market: Inside the outsourcing space

Play Episode Listen Later Aug 15, 2025 52:52


In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Claire Riches, Vice President, Clinical Solutions at Citeline. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Claire, covering: Being involved in the clinical development and commercial launch of a little mega-blockbuster, called... Viagra. Her first exposure to outsourcing at a small biotech, and the importance of partnerships in progressing the pipeline. Ignoring the pharma industry snobbery, and opting to move into the fast and varied world of CROs. Timeless sponsor and provider partnership tips, including the importance of aligned intentions, especially with biotechs. How are the tailwinds for rare diseases, meeting unmet patient needs, AI/data, and personalised medicines driving demand at Citeline? With over 30 years' experience in the life science sector, Claire is a passionate advocate of bringing drug development to life. Having worked in large pharma, biotech and the CRO space, Claire uses her platform to raise awareness of the challenges the industry is facing, and how as a collective voice, we can solve big, challenging questions. She believes strongly in the need to ask questions of the industry to drive change, which in turn drives innovation and growth. Claire speaks regularly through various forums on the topics of Women in Science, Impacts of Politics and Economics on Drug Development and Drug Access, and Evolution and Efficiency of Drug Development pathways. She is currently focused on levelling the playing field for the Biotech industry via her podcast Small Biotech, Big Decisions | Citeline   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!

Research To Practice | Oncology Videos
Multiple Myeloma | Oncology Q&A for Patients: Clinical Experts Address Common Questions Posed by Patients with Relapsed/Refractory Multiple Myeloma

Research To Practice | Oncology Videos

Play Episode Listen Later Aug 15, 2025 62:11


Featuring perspectives from Dr Natalie S Callander and Dr Sagar Lonial, including the following topics:  Introduction: Multiple Myeloma — 2005 to 2025 (0:00) Questions from the Beginning (7:53) Choosing Options (13:54) Clinical Trials (18:03) Neuropathy (23:55) Chimeric Antigen Receptor (CAR) T-Cell Therapy (28:40) Bispecific Antibodies (35:18) Antibody-Drug Conjugates (43:08) Interacting with the Oncology Team (51:47) Other Questions (57:30) Educational and presenter information

The Future of Everything presented by Stanford Engineering

Neurologist Michelle Monje studies the close relationship between cancer and the nervous system, particularly in an aggressive brain cancer that often strikes in childhood. Her research shows that the cancer cells are electrically integrated into the brain itself and these connections actually help the cancer to grow. Monje and collaborators have now developed an immunotherapy that has shown great promise in mice and early human trials. One patient had a “complete response” and is cancer-free four years after treatment, Monje tells host Russ Altman on this episode of Stanford Engineering's The Future of Everything podcast.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: Michelle MonjeConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Michelle Monje, a professor of pediatric neurology at Stanford University.(00:03:39) Focus on Cancer ResearchMonje's clinical observations led to exploring cancer-neuron interactions.(00:05:28) Neurons and Glial CellsThe role of neurons and glial cells in brain function and disease.(00:08:32) Gliomas in ChildrenAn overview of gliomas and their origins in glial precursor cells.(00:10:12) Rethinking Brain Cancer BehaviorHow gliomas don't just grow—they integrate with brain circuits.(00:14:49) Mechanisms of Tumor GrowthTwo primary mechanisms by which cancer exploits the nervous system.(00:16:32) Synaptic Integration of Cancer CellsThe discovery that glioma cells form synapses with neurons.(00:20:06) CAR T-Cell TherapyAdapting CAR T-cell immunotherapy to target brain tumors.(00:22:52) Targeting GD2 AntigenIdentification of a surface marker enables precision CAR T-cell therapy.(00:24:35) Immune Access to the BrainThe ability of CAR T-cells to reach the brain, despite prior understanding.(00:26:16) First Clinical Trial ResultsThe significant tumor reduction and response from CAR T-cell therapy.(00:28:21) Combined TherapiesPairing immune therapy with neural signaling blockers for better outcomes.(00:30:35) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook

It Takes Balls
Christopher Beck's Story of Recurrences, High-Dose Chemo, and Clinical Trials

It Takes Balls

Play Episode Listen Later Aug 15, 2025 40:01


In this episode of It Takes Balls, 29-year-old Christopher Beck shares his intense and ongoing fight against a rare and aggressive form of testicular cancer - one that didn't even begin in his testicle.Christopher opens up about the strange onset of symptoms that eventually led to a stunning diagnosis: embryonal carcinoma presenting as a retroperitoneal mass. Despite having no tumors in his testicles, pathology confirmed testicular cancer, placing him in a rare category of patients with extragonadal germ cell tumors.What follows is a relentless journey: four rounds of BEP chemotherapy, followed by a post-chemo RPLND at Indiana University. Christopher thought he was in the clear until new scans revealed a recurrence a few months later. What began as one battle turned into two, then three. He entered a clinical trial and underwent high-dose chemotherapy with stem cell rescue.Now, Christopher is enrolled in a cutting-edge CAR T-cell therapy trial - a hopeful step forward. He shares candid reflections on the mental weight of recurrence, the isolation of dealing with a rare cancer, and the importance of keeping faith while making space for both grief and gratitude.Christopher also speaks openly about how cancer reshaped his identity, tested his relationships, and pushed him to live more deliberately, with purpose, presence, and patience.Join The Ball Room:https://www.testicularcancerawarenessfoundation.org/theballroomWant to be a guest? Apply here:https://www.testicularcancerawarenessfoundation.org/it-takes-balls-submissionsFollow Testicular Cancer Awareness Foundation:⁠https://www.testescancer.orghttps://www.twitter.com/testescancer⁠⁠https://www.instagram.com/testescancerhttps://www.facebook.com/tca.orgFollow Steven Crocker: https://www.twitter.com/stevencrockerhttps://www.instagram.com/stevencrockerhttps://www.facebook.com/steven.crocker2Connect with Christopher:beck.r.christopher@gmail.comTheme song: No Time Like Now - Tom Willner www.tomwillner.com

MedEvidence! Truth Behind the Data

MedEvidence! Truth Behind the Data

Play Episode Listen Later Aug 15, 2025 10:14 Transcription Available


Send us a textDr. Michael Koren Joins Kevin Geddings to discuss how the current political situation in Washington, D.C. is interfering with clinical research. They discuss the Vaxart trial, that is looking at the next generation of oral COVID vaccines, and how it has been affected by the Trump administration's inconsistent orders regarding vaccines. Dr. Koren points out that the Vaxart trial doesn't actually use mRNA and is poised to be a solution beyond this technology, but that the administration has stopped (at least temporarily) this research anyway.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

SurgOnc Today
SSO Education Series: Increasing Patient Diversity in Clinical Trials

SurgOnc Today

Play Episode Listen Later Aug 14, 2025 49:08


In this episode of SurgOnc Today, Drs. Oluwadamilola "Lola" Fayanju and Jose Trevino moderate a conversation with Drs. Ugwuji Maduekwe and Rebecca Snyder on the importance of patient diversity in clinical trials as they also provide  systemic, investigator-led, and patient-level strategies to facilitate enrollment of diverse trial participants.

MedEvidence! Truth Behind the Data

MedEvidence! Truth Behind the Data

Play Episode Listen Later Aug 13, 2025 45:56 Transcription Available


Send us a textRadiologist Sue Jane Grosso-Rivas, MD joins cardiologist and clinical researcher Michael J. Koren, MD to share her inspiring journey from aspiring secretary to Medical Co-Director of Breast Imaging at Summit Health. The doctoral duo discuss how Dr. Grosso-Rivas's career was shaped by a school counselor who recognized her potential and encouraged her ambition.Dr. Grosso-Rivas explains the fundamentals of breast mammography: when patients should begin screening, and how to ensure high-quality care for breast cancer prevention. She then explores what happens if mammography finds an abnormality, including if it is benign, suspicious, or indicative of cancer.This is part one of a two-part series.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

OffScrip with Matthew Zachary
LEAD EP2 : Stop the Spiral

OffScrip with Matthew Zachary

Play Episode Listen Later Aug 12, 2025 11:30


As the lead wreaks havoc on Cooper's development, Shannon searches for answers. Desperate to get a handle on what was happening to her son, she grabs onto a lifeboat - nursing school. Andy tries to piece together the past to make sense of the present.LEAD how this story ends is up to us is a true story written and produced by Shannon Burkett. Co-produced by Jenny Maguire. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper BurkettEP2 features Keith Nobbs and Frank Wood. Music by Peter Salett. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes. Casting by Alaine Alldaffer and Lisa Donadio.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Boost Your Biology with Lucas Aoun
331. How Light Controls Your Hormones, Sleep and Health (Must Know!)

Boost Your Biology with Lucas Aoun

Play Episode Listen Later Aug 10, 2025 60:36


In this episode of the Boost Your Biology podcast, Lucas Aoun interviews Andy Mant, CEO and founder of Bon Charge, discussing his journey from health struggles to creating a successful wellness brand. They explore the science behind blue light blocking glasses, the evolution of the product line, and the impact of synthetic light on health. The conversation also delves into optimizing sleep and circadian rhythms, as well as future research plans for customer feedback and product efficacy. In this conversation, Andy Mant discusses the advancements and challenges in the field of red light therapy, including the importance of regulatory approvals and the prevalence of counterfeit products. He shares insights on the evolution of red light therapy devices, the integration of holistic health practices, and the emerging research on testosterone optimization. The discussion also covers the potential of pulsed electromagnetic fields (PEMF) as a complementary therapy and the future of biohacking and personalized medicine. Finally, Andy reflects on his entrepreneurial journey, emphasizing the significance of hiring the right talent to foster business growthRelevant links:Andy Mant's website: https://au.boncharge.com/Check Out My Website For Coaching, Recommended Products and Much More:https://www.boostyourbiology.com/Disclaimer:The information provided in this podcast episode is for entertainment purposes and is NOT MEDICAL ADVICE. If you have any questions about your health, contact a medical professional. This content is strictly the opinions of Lucas Aoun and is for informational and entertainment purposes only. It is not intended to provide medical advice or to take the place of medical advice or treatment from a personal physician. All viewers of this content are advised to consult with their doctors or qualified health professionals regarding specific health questions. Neither Lucas Aoun nor the publisher of this content takes responsibility for possible health consequences of any person or persons reading or following the information in this content. All consumers of this content especially taking prescription or over-the-counter medications should consult their physician before beginning any nutritional, supplement or lifestyle program.Chapters00:00 The Journey Begins: From Health Struggles to Entrepreneurship03:02 The Science of Light: Understanding Blue Light and Its Effects05:48 Creating Effective Blue Light Blockers: The Evolution of Bon Charge08:41 Quality Matters: The Importance of Effective Blue Light Blocking11:35 The Role of Lenses: Dark vs. Clear in Blue Light Blocking14:18 Customer Feedback and Product Evolution: Responding to Demand17:10 Circadian Rhythms: The Importance of Natural Light Exposure22:24 Mimicking Ancestral Light Exposure23:28 The Detrimental Effects of Synthetic Light26:28 Optimizing Eating Patterns for Better Metabolism28:55 Clinical Trials and Product Efficacy31:13 Navigating the Red Light Therapy Market33:24 Holistic Approaches to Skin Health33:59 Red Light Therapy and Testosterone Optimization36:12 Understanding PEMF Therapy37:46 The Future of Biohacking38:57 Advice for Aspiring Entrepreneurs Hosted on Acast. See acast.com/privacy for more information.

The James Cancer-Free World Podcast
Episode 193: The Nation's First Telemedicine Cancer Clinical Trial, with Dr. Sameek Roychowdhury

The James Cancer-Free World Podcast

Play Episode Listen Later Aug 7, 2025 29:51


A new clinical trial at the James is pioneering the use of telemedicine to create better treatment options for patients with a rare form of pancreatic cancer. “This is the first nationwide telemedicine therapeutic clinical trial for cancer,” said Sameek Roychowdhury, MD, PhD, a physician scientist and leader in creating innovative ways to look at, understand and treat cancer. “It's a new way of thinking and providing access to clinical trials.” Roychowdhury and his team at the James identified the fibroblast growth factor receptor (FGFR) gene and how “using a smart drug we could turn it off and slow the cancer growth” it caused. A traditional clinical trial using the smart drug showed promising results in patients with pancreatic cancer and the FGFR gene. Because this was a rare type of cancer, a national clinical trial would be costly. “How do we give patients access to this?” Roychowdhury said. The answer came during the COVID pandemic and the increased use of telemedicine. “That allowed us to connect the dots and utilize telemedicine,” he said. After a lengthy regulatory and approval process that created a well-thought out and workable plan, the clinical trial began in May. Patients identified with pancreatic cancer and the FGFR gene will be able to remain at home and coordinate their treatment with their local oncologists and Roychowdhury and his team, who will work in tandem. “Instead of a clinical trial in 50 locations and a $20 million price tag, we've reduced the cost to $2 million,” he said. Roychowdhury believes this clinical trial will lead to others for rare cancers and make it more cost effective for pharmaceutical companies to create smart drugs for rare forms of cancer. He is working to create a national alliance of oncologists to share ideas, best practices and create more telemedicine clinical trials for rare types of cancers that would otherwise never be opened. “We have identified seven more targets and clinical trials [here at the James],” Roychowdhury said.

JAMAevidence JAMA Guide to Statistics and Methods
Factorial Clinical Trial Designs With Dr Ciolino

JAMAevidence JAMA Guide to Statistics and Methods

Play Episode Listen Later Aug 7, 2025 19:07


Jody D. Ciolino, PhD, Northwestern University, Feinberg School of Medicine discusses Factorial Clinical Trial Designs with JAMA Statistical Editor Roger J. Lewis, MD, PhD Related Content: Factorial Clinical Trial Designs Reporting of Factorial Randomized Trials

WCG Clinical Services Fireside Chats
Advancing Imaging in Clinical Trials Using AI

WCG Clinical Services Fireside Chats

Play Episode Listen Later Aug 6, 2025 21:12


In this episode of WCG Talks Trials, Silvio Galea, chief data and analytics officer, and Bryan Wayne, vice president of imaging operations, both of WCG, explore the critical role of imaging in clinical trials. Together, they break down industry acronyms, unpack the process of independent image review, and discuss how WCG is contributing to the validation and implementation of AI-driven radiology solutions. Listen in as they share behind-the-scenes insights into core lab operations, the significance of sample size and study design, and how emerging technology is shaping the future of clinical research. Whether you are a clinical trial professional, healthcare innovator, or simply curious about the intersection of AI and research, this episode provides valuable perspectives on driving efficiency, accuracy, and better outcomes in clinical research imaging. For more information about WCG's imaging solutions, visit wcgclinical.com/imaging.  

Foundation Fighting Blindness
Wet AMD Treatment Susvimo Preserves Vision for Five Years in Phase 3 Clinical Trial

Foundation Fighting Blindness

Play Episode Listen Later Aug 6, 2025 3:05


Susvimo is an FDA-approved treatment that continuously delivers drug through a tiny, implanted capsule

MedEvidence! Truth Behind the Data

MedEvidence! Truth Behind the Data

Play Episode Listen Later Aug 6, 2025 17:19 Transcription Available


Send us a textDermatologist Dr. Kristen Stewart digs deep to get to the root of psoriasis, a skin condition that affects approximately 3% of Americans. She talks about the role of systemic inflammation and how excessive inflammation can impact multiple body systems beyond just the skin. Dr. Stewart reviews her experience treating psoriasis, differentiating it from eczema, and the improvements in modern treatments. Dr. Stewart explains that newer treatment options have revolutionized management approaches, shifting goals from simply reducing symptoms to achieving near-complete clearance and addressing the underlying inflammation.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Surfing the Nash Tsunami
6.9.3 - Expert: Naim Alkhouri Discusses His Long Friendship with Stephen Harrison and His New Role at Summit Clinical Research

Surfing the Nash Tsunami

Play Episode Listen Later Aug 6, 2025 29:12


Send us a textHepatologist and hepatology key opinion leader Naim Alkhouri joins Roger Green to remember his longstanding relationship with Stephen Harrison, announce his new role as Chief Academic Officer at Summit Clinical Research and share how, in this role, he will have exciting new avenues make an impact on many elements of MASH drug development and patient care. The conversation can be divided into two sections. In the first, Naim recounts his relationship with Stephen Harrison, beginning with his move to a different San Antonio clinical trial practice and continuing through his tenure at Arizona Liver Health, up until Stephen's untimely passing last April. He describes what it was like to work with Stephen, the man, and to learn from and share ideas with Stephen, the "visionary." Next, Naim announces that he has joined Summit Clinical Research as Chief Academic Officer. He describes the many aspects of his new role, from collaborating with Gail Hinkson, Mazen Noureddin and the rest of the Summit team in designing better clinical trials to the many kinds of medical education Summit can bring to various medical stakeholders. He describes the dramatic growth in the number of trial sites in the Summit network and additional growth he foresees. Like Gail Hinkson in the same episode, he discusses ways in which Alzheimer's drug development is similar to MASH. He also touches on obesity trials and the ways that Summit can help create more robust knowledge about obesity, not only through trials but also expert advisory boards. In the end, he makes a personal announcement that you will have to read to learn.

OffScrip with Matthew Zachary
LEAD EP1: The Monster in the Walls

OffScrip with Matthew Zachary

Play Episode Listen Later Aug 5, 2025 22:39


A mysterious dust fills a young family's apartment. The truth begins to unravel when the mother gets a call from the pediatrician - the monster deep within the walls has been unleashed. LEAD how this story ends is up to us is a true story written and produced by Shannon Burkett. Co-produced by Jenny Maguire. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett. EP1 features Zak Orth, Jenny Maguire, Daphne Gaines, and Micheal Gaston. Music by Peter Salett. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes. Casting by Alaine Alldaffer and Lisa Donadio.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Sapio with Buck Joffrey
147: The Wrong Vitamin E Supplement Can Hurt You

Sapio with Buck Joffrey

Play Episode Listen Later Aug 4, 2025 34:53


In this conversation, Dr. Barrie Tan joins Dr. Buck Joffrey to discuss the significance of tocotrienols—a lesser-known form of vitamin E—and their potential role in preventing chronic disease and promoting healthy aging. Dr. Tan explains the differences between tocopherols and tocotrienols, the role of vitamin E in human health, and highlights the annatto plant as a key natural source of tocotrienols. The discussion also touches on clinical trials, the anti-inflammatory effects of tocotrienols, and how they work in synergy with other supplements. Learn more about Dr. Barrie Tan: https://barrietan.com/ - Download Dr. Buck Joffrey's FREE ebook, Living Longer for Busy People: https://ru01tne2.pages.infusionsoft.net/?affiliate=0 Book a FREE longevity coaching consultation with Dr. Buck Joffrey: https://coaching.longevityroadmap.com/

Life Science Success
Clinical Trials Insider: Patient-Centric Strategies with Lauri Befus

Life Science Success

Play Episode Listen Later Aug 4, 2025 25:09


Send us a textIn this episode of the Life Science Success Podcast my guest is Lauri Befus, Vice President of Clinical Operations at M3 Wake Research, a leading integrated site network in the United States. With over 13 years of experience in clinical research and healthcare operations, Lauri brings a unique perspective to clinical trials, focusing on patient-centric strategies and operational excellence.00:00 Introduction to Life Science Success Podcast00:37 Meet Lauri Befus: Vice President of Clinical Operations at M3 Wake Research00:59 Lauri's Journey into Clinical Research01:53 Educational Background and Early Career02:36 Career Progression and Key Milestones04:25 Challenges in the Life Sciences Industry05:18 Diversity and Inclusion in Clinical Trials06:16 Overview of M3 Wake Research07:37 Lauri's Role and Responsibilities13:59 Innovative Projects and Initiatives16:28 Future Goals and Industry Innovations17:31 Leadership Insights and Advice24:19 Conclusion and Final Thoughts

MedEvidence! Truth Behind the Data

MedEvidence! Truth Behind the Data

Play Episode Listen Later Aug 4, 2025 9:04 Transcription Available


Send us a textThe back-to-school season represents an ideal time to reset health priorities and schedules, potentially more impactful than New Year's resolutions. Dr. Michael Koren joins Kevin Geddings to discuss how the changes that come with a new school year also include health changes and the inevitable spread of the flu. They talk about how new initiatives like BARDA, sponsored by the US Department of Health and Human Services, aim to give new ways to fight diseases like the flu in these changing times.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

ESC Cardio Talk
Journal editorial - Has artificial intelligence proven stress perfusion cardiac computed tomography obsolete or more relevant than ever?

ESC Cardio Talk

Play Episode Listen Later Aug 4, 2025 15:52


Decentralized: The Decentralized Trials & Research Podcast
A Pathway to use Site-Selected Technology in Clinical Trials

Decentralized: The Decentralized Trials & Research Podcast

Play Episode Listen Later Aug 4, 2025 56:27


2025-08-01 Hosts Dr. Amir Kalali and Jane Myles discussied DTRA's Bring Your Own Technology initiative with leaders Brandon Maggio (GSK) and Joe Dustin (Dauntless eClinical Strategies).Sites are managing 20+ systems per trial, leading to fatigue and friction. DTRA's BYOT (Bring Your Own Technology) initiative aims to empower sites to use their own validated tools like eConsent and eSource. Hear how this approach streamlines workflows, improves data quality, and puts sites and patients first.BYOT Playbook -- https://www.dtra.org/bring-your-own-technology

Oncology Peer Review On-The-Go
S1 Ep173: Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Oncology Peer Review On-The-Go

Play Episode Listen Later Aug 4, 2025 23:31


In a discussion with CancerNetwork®, Jacob Sands, MD, assistant professor of Medicine at Harvard Medical School, thoracic oncologist at the Dana-Farber Cancer Institute, and investigator of the phase 2 TROPION-Lung05 trial (NCT04484142) and phase 3 TROPION-Lung01 trial (NCT04656652), which supported the accelerated approval of datopotamab deruxtecan-dlnk (dato-DXd; Datroway) in pretreated EGFR-mutant metastatic NSCLC in June 2025, discussed safety and efficacy considerations for the agent's use.1-3 He began by outlining a combined cohort of the TROPION-Lung05 and TROPION-Lung01 trials, which collectively showed an efficacy benefit with dato-DXd in patients with EGFR-mutant disease vs docetaxel. In the combined cohort, the median progression-free survival with dato-DXd reached 5.8 months, and the median overall survival was 15.6 months. Additional efficacy data revealed an objective response rate of 45% (95% CI, 35%-54%) and a median duration of response of 6.5 months (95% CI, 4.2-8.4).  Furthermore, Sands highlighted the most common toxicities observed with dato-DXd in this population, which included stomatitis, interstitial lung disease (ILD), and ocular toxicities. He also reviewed management strategies to mitigate their incidence and severity. Specifically, remedies include prophylaxis, oral hygiene, and dose reductions for stomatitis; using preservative-free eye drops and ophthalmology visits for ocular toxicity management and prevention; and monitoring for any incidence of high-grade ILD. He then touched upon next steps for research in this disease state, including the phase 2 ORCHARD trial (NCT03944772) evaluating dato-DXd with osimertinib (Tagrisso) in the second-line setting after progression on osimertinib and the phase 3 TROPION-Lung15 trial (NCT06417814), which is evaluating chemotherapy vs dato-DXd alone or with osimertinib.4,5 Sands concluded by discussing the implications for toxicity management in patients who experience responses that exceed median outcomes, suggesting that the toxicity profile may be more severe for this group. Emphasizing the broadness of outcomes with any drug, he expressed that patients with experiences that deviate from the observed median outcome are an important consideration for clinical practice. References Sands J, Ahn MJ, Lisberg A, et al. Datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer with actionable genomic alterations: results from the phase II TROPION-Lung05 study. J Clin Oncol. Published online January 6, 2025. doi:10.1200/JCO-24-01349 Ahn MJ, Tanaka K, Paz-Ares L, et al. Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 study. J Clin Oncol. Published online September 9, 2024. doi:10.1200/JCO-24-01544  FDA grants accelerated approval to datopotamab deruxtecan-dlnk for EGFR-mutated non-small cell lung cancer. News release. FDA. June 23, 2025. Accessed July 29, 2025. https://tinyurl.com/mtay7ab9 Yu HA, Goldberg SB, Le X, et al. Biomarker-directed phase II platform study in patients with EGFR sensitizing mutation-positive advanced/metastatic non-small cell lung cancer whose disease has progressed on first-line osimertinib therapy (ORCHARD). Clin Lung Cancer. 2021;22(6):601-606. doi:10.1016/j.cllc.2021.06.006 A study to investigate the efficacy and safety of dato-DXd with or without osimertinib compared with platinum based doublet chemotherapy in participants with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (TROPION-Lung15). ClinicalTrials.gov. Updated July 16, 2025. Accessed July 29, 2025. https://tinyurl.com/56z3dmsp

Pharma Intelligence Podcasts
Exploring Ex-US Markets to Reduce Risk for Your Clinical Trials

Pharma Intelligence Podcasts

Play Episode Listen Later Aug 1, 2025 18:03


Amid growing uncertainty in the U.S. regulatory landscape, sponsors are increasingly looking to ex-U.S. markets as a strategic way to reduce clinical trial risk and maintain momentum. In this episode, Novotech experts Renita Hite and Scott Schliebner discuss how biotech and small to mid-sized pharma companies are adapting their global trial strategies—leveraging regions like APAC and Eastern Europe for faster startups, strong data quality, and significant cost savings. They explore: -Why sponsors are increasingly looking outside the U.S. amid regulatory and political uncertainty -Key benefits of ex-U.S. regions like APAC and Eastern Europe, including speed, quality, and cost savings -Strategic considerations for integrating global sites into clinical development plans -Common pitfalls and risk mitigation strategies when operating in international markets -How ex-U.S. trials support greater flexibility and resilience heading into 2025–2026 This episode is part 3 of 4 in the series “Navigating Regulatory Changes & Market Dynamics: CRO Perspectives on the Future of Clinical Trials”, featuring insights from Novotech on evolving trends impacting global clinical development. Stay tuned for the next episode, where we'll continue exploring the key forces shaping the future of clinical trials. Listen to part 1 here: Podcast Series: Navigating Regulatory Changes & Market Dynamics: CRO Perspectives on the Future of Clinical Trials Listen to part 2 here: Podcast Series: Navigating Regulatory & Market Shifts — CRO Perspectives on Clinical Trials

Surfing the Nash Tsunami
6.9 - Complexities of Behavior Change, Devices That Can Help, Future of Clinical Trials and MedEd

Surfing the Nash Tsunami

Play Episode Listen Later Aug 1, 2025 77:21


Send us a text00:00:00 - Surf's Up: Episode 6.9This conversation covers three topics. The first discusses the challenges of behavior change in dietary habits and ways governments can help, the second looks at what one can learn from wearing a CGM for 30 days, and the third celebrates the late Stephen Harrison while looking into the future of clinical trials and medical education. 00:06:12 - Global Think-Tank on SLD Roundtable, Part 3Behavior consultant Dr. Kristina Curtis joins Jörn Schattenberg, Louise Campbell and Roger Green to discuss issues related to patient-centered care. This conversation starts by focusing on the unique challenges that come with changing dietary habits. Changing this behavior is so challenging because the issues are so complex. People lack education about healthy eating habits. Even when they do, the high-pressure world in which we live often makes it easier simply to offer children fast food. Even parents who know better might allow their children (or spouses, or selves) not to eat vegetables after a trying day. The panel proceeds to discuss steps politicians can take to encourage healthier living and lifestyles if they wish, and why some are easier to execute than others. Finally, the group shares why they felt "enlightened" when leaving the SLD, and perhaps a little less alone. 00:21:34 - Newsmaker: Fatty Liver Alliance President Mike BetelThis interview with Fatty Liver Alliance President Mike Betel focuses on Year 3 of his 30-day Glucose Challenge. Mike wears a continuous glucose monitor (CGM) for the entire month of July and provides daily videos on LinkedIn and the Fatty Liver Alliance website discussing what he learned. The first year was dedicated to teaching the impact of eating badly and the second year was similar, but less egregious. This year, Mike, who is pre-diabetic, set the goal of keeping his glucose in a "normal" range of 70-140 mg/dl. He did so successfully 97-98% of the time over the month, and discusses some of the tricks he learned that help keep glucose in range over that time (HINT: walking 10-15 minutes after meals helps a lot!). He also shares hints about how to look at overall weight (it's the fat that matters, not simple weight), why it is not healthy to believe you must finish every bite of food put in front of you, and how all this relates to sleep and overall health. He also provides seeds for thought about ways manufacturers and providers might educate patients effectively on these issues. 00:53:11 - Expert: Summit Clinical Research Chief Academic Officer Naim AlkhouriThis interview occurred in late April during our episode celebrating Stephen Harrison. Naim chose this interview to annouce that he was joining Summit as Chief Academic Officer. The first part of this discussion focuses on Stephen on two levels: the personal history between Naim and Stephen and the nature of the contributions Stephen has made to the science of MASH, and particularly clinical trial design. The second part of the interview discusses Naim's new role, the diffrent kinds of teaching, training and medical education he sees as pivotal to the future of MASLD and MASH therapies, and the other elements of his new role. While discuss the role, he shares several bright, challenging insights about when MASH-ville is heading. 01:15:09 - ConclusionThe business report discusses vacations on the SurfingMASH team, upcoming episodes, and grateful notes from Ukrainian listeners. 

Neurology Minute
Updates in Neuroinfectious Diseases - Part 8

Neurology Minute

Play Episode Listen Later Jul 30, 2025 3:42


In part eight of this ten-part series, Dr. Paul Crane and Dr. Prashanth Ramachandran discuss the study findings and the potential impact on clinical practice.  Show reference:  https://jamanetwork.com/journals/jamaneurology/fullarticle/2824325

JAMA Network
JAMA Cardiology : Preserving and Promoting Clinical Trial Representativeness

JAMA Network

Play Episode Listen Later Jul 30, 2025 16:03


Interview with Roxana Mehran, MD, author of Preserving and Promoting Clinical Trial Representativeness: A Review of Existing Strategies and the Path Forward. Hosted by Robert Bonow, MD. Related Content: Preserving and Promoting Clinical Trial Representativeness

MedEvidence! Truth Behind the Data

MedEvidence! Truth Behind the Data

Play Episode Listen Later Jul 30, 2025 21:57 Transcription Available


Send us a textCardiothoracic surgeon Dr. Mustafa "Dr. Kurk" Kurkluoglu joins cardiologist Dr. Michael Koren to discuss three mechanisms that affect heart health:Oxidative stress, dangerous charged particles that can damage cellsInflammation, an immune process that can get out of controlEndothelial dysfunction, cells that line blood vessels stop working properlyThe two doctors discuss what can be done to address some of these issues, including supplements and the evidence  (or lack thereof) supporting their use. Finally, they talk about Dr. Kurk's upcoming book, The Three Musketeers of Heart Health, which is available here.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

JAMA Cardiology Author Interviews: Covering research in cardiovascular medicine, science, & clinical practice. For physicians

Interview with Roxana Mehran, MD, author of Preserving and Promoting Clinical Trial Representativeness: A Review of Existing Strategies and the Path Forward. Hosted by Robert Bonow, MD. Related Content: Preserving and Promoting Clinical Trial Representativeness

Irish Tech News Audio Articles
Ground-breaking first-in-human cancer cell therapy trials to start in Galway

Irish Tech News Audio Articles

Play Episode Listen Later Jul 30, 2025 6:10


Clinical researchers are set to launch immune-cell therapy clinical trials aimed at tackling treatment resistance in solid tumour, supported by a €11.9 million grant from the Disruptive Technologies Innovation Fund. The project is being spearheaded by a consortium from LIfT BiSciences, University of Galway, Galway University Hospitals and Hooke Bio. The funding award, announced by Minister for Enterprise, Trade and Employment, Peter Burke T.D., and Minister for Further and Higher Education, Research, Innovation and Science, James Lawless T.D., is the largest single grant awarded by the Disruptive Technologies Innovation Fund to date, with €5.9 million in direct funding going to University of Galway. The consortium will launch the first-in-human clinical trials of a ground-breaking neutrophil-based cancer immune-cell therapy developed by LIfT BioSciences, a client of Údarás na Gaeltachta with an Irish base in An Spidéal, Co. Galway. Neutrophils are part of the first line of defence in the body's immune response. The trial will focus on patients with metastatic cervical and head and neck cancer who have exhausted all standard treatments, including checkpoint inhibitors. Trials, which will be conducted at Galway University Hospitals, are expected to begin in 2026. The grant will support the clinical development of LIfT BioSciences' next-generation cell therapy designed to overcome resistance in solid tumours, known as Immuno-Modulatory Alpha Neutrophils (IMANs). University of Galway will contribute its deep expertise in oncology and cell therapy clinical trials, as well as in translating laboratory research into clinical applications, including predictive biomarkers. Hooke Bio will provide advanced analytical tools to optimise and assess how patients respond to this novel therapy. The study will first establish the safe and effective dose of immune-cell cancer therapy and then combine this treatment with other immune-based therapies to overcome resistance to these cancer treatments observed in some patients. Professor Sean Hynes, Consultant Histopathologist and Translational Cancer Researcher from University of Galway's School of Medicine and Lead Academic of the award said: "In partnership with LiFT BioSciences and Hooke Bio, we are very excited about University of Galway and Galway University Hospital being at the forefront of delivering on new oncological cellular therapies by using neutrophils, the body's own first responders, in the fight against cancer and ensuring patients in the West of Ireland have access to such cutting edge treatments." Professor Fidelma Dunne, Director of the Institute for Clinical Trials at University of Galway, said: "The Institute for Clinical Trials is proud to support this collaboration and look forward to working closely with Disruptive Technologies Innovation Fund partners LifT BioSciences and Hooke Bio, and with academic and clinical colleagues at the University and Galway University Hospital. The programme will bring a new therapy to patients with an unmet critical need. This will be a truly inspirational journey from basic science to a first in human trial as we deliver this novel cell therapy to cancer patients." Dr Michael McCarthy, Consultant Medical Oncologist and Principal Investigator at University Hospital Galway, added: "Cancer remains one of the most complex and dynamic diseases. IMANs have the potential to overcome key limitations of current cancer treatments by activating both the innate and adaptive branches of the immune system. This dual stimulation enables a comprehensive anti-tumour response, representing a transformative advancement in cancer therapy. We are pleased to receive this grant in collaboration with LIfT and Hooke Bio, and we look forward to accelerating the clinical development of this groundbreaking immunotherapy." Dr Andrew Finnerty Manager of the Centre for Cell Manufacturing Ireland at University of Galway, said: "We at the Centre for Cell Manufacturing Ire...

OffScrip with Matthew Zachary
Meet My Grief: Notes from an Orphaned Teen

OffScrip with Matthew Zachary

Play Episode Listen Later Jul 29, 2025 43:41


Lexi Silver is 15 years old. She lost both of her parents before she turned 11. That should tell you enough—but it doesn't. Because Lexi isn't here for your pity. She's not a sob story. She's not a trauma statistic. She's a writer, an advocate, and one of the most emotionally intelligent people you'll ever hear speak into a microphone.In this episode, Lexi breaks down what grief actually feels like when you're a kid and the adults around you just don't get it. She talks about losing her mom on Christmas morning, her dad nine months later, how the system let her down, and how Instagram trolls tell her she's faking it for attention. She also explains why she writes, what Experience Camps gave her, how she channels anger into poems, and what to say—and not say—to someone grieving.Her life isn't a Netflix drama. But it should be.And by the way, she's not “so strong.” She's just human. You'll never forget this conversation.RELATED LINKS• Lexi on Instagram: @meet.my.grief• Buy her book: The Girl Behind Grief's Shadow• Experience CampsFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Summits Podcast
Epi 91: Volunteerism and raising the next generation of cancer fighters with Lori Wheeler

Summits Podcast

Play Episode Listen Later Jul 29, 2025 30:36


In episode 91 of the Summits Podcast, co-hosts Vince Todd, Jr. and Daniel Abdallah are joined by long-time Heroes Foundation volunteer Lori Wheeler. Tune in as Lori shares the cancer stories that have shaped her family and how she is raising her children to make a difference in their communities.

Surfing the Nash Tsunami
S6 E8.3 - Deep Dive into Drug Development IV: Other Modes Of Action; Metabolic vs. Pleiotropic Effects

Surfing the Nash Tsunami

Play Episode Listen Later Jul 29, 2025 16:59


Send us a textThis conversation is the fourth and final segment of SurfingMASH's April discussion of drug development in memory of Stephen A. Harrison. In addition to co-hosts Jörn Schattenberg, Louise Campbell and Roger Green, panelists include hepatologist and key opinion leader Sven Francque. The discussion focuses on PPARs, genetic medicines, and other emerging drug classes while considering the idea that drug therapies can have an impact on the liver independent of their effect on fibrosis regression. It begins with Sven  discussing his experience as a lead investigator in clinical trials for the pan-PPAR agonist lanifibranor, whose Phase 3 trial is now fully recruited. Sven states that in addition to fibrosis regression, lanifibranor is likely to exhibit other pleiotropic effects, and notes that vascular changes start early in the fibrotic progression process. After Sven elaborates on these effects, Louise asks about the SCD-1 agent Aramchol. This leads to a discussion about the idea that over time, therapy will probably come to incorporate two separate modes of action, with one to treat the metabolic dysfunction and the other to treat specific effects in the liver or, as Jörn puts it, "combining weight-neutral and weight-reducing drugs." This evolves into a discussion of what Louise terms "personal-centric" medicine, or what patient advocate Mike Betel has previously described on SurfingMASH as "tailored medicine."The rest of the conversation predominantly lists other classes of drugs, "safe" mitochondrial uncouplers, genetic medicines, and others. Roger inquires about the FASN inhibitors, which are entering Phase 3 clinical trials. Jörn says that the data appears positive and unique. That said, he and Sven agree we need more data.Louise sounds the closing note for this roundtable by discussing our co-founder, Stephen Harrison, and the energy and enthusiasm he brought to the entire drug development process. The group agrees that Stephen's impact continues to be felt through the MASLD community, even as he is missed by us all.

Huberman Lab
Male vs. Female Brain Differences & How They Arise From Genes & Hormones | Dr. Nirao Shah

Huberman Lab

Play Episode Listen Later Jul 28, 2025 146:58


My guest is Dr. Nirao Shah, MD, PhD, a professor of psychiatry, behavioral sciences and neurobiology at Stanford University School of Medicine. We discuss how the brains of males and females differ and how those differences arise from different genes and hormones during fetal development, in childhood and adulthood. We discuss what drives male- versus female-specific behaviors and how hormonal fluctuations across the lifespan, including puberty, the menstrual cycle, menopause and aging – affect behavior, cognition and health. Additionally, we discuss how biology relates to gender identity and the impact of hormone therapies on brain circuits that regulate mating, parenting and social bonding. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman Maui Nui: https://mauinuivenison.com/huberman Eight Sleep: https://eightsleep.com/huberman LMNT: https://drinklmnt.com/huberman Function: https://functionhealth.com/huberman Timestamps 00:00:00 Nirao Shah 00:02:11 Mice, Humans & Brain, Biological Conservation 00:05:25 Hormones, Nature vs Nurture 00:07:13 Biological Sex Differences, Chromosomes & SRY Gene, Hormones 00:16:01 Sponsors: Maui Nui & Eight Sleep 00:19:09 Androgen Mutations, Feminization & Masculinization 00:22:04 SRY Gene; Animals & Sexual Trans-Differentiation 00:27:49 Hormones & Biological Brain Differentiation 00:31:22 Congenital Adrenal Hyperplasia, Androstenedione; Stress & Pregnancy 00:35:56 Genes, Brain Differentiation & Sexual Identity; Congenital Adrenal Hyperplasia 00:43:37 Testosterone, Estrogen & Brain Circuits 00:47:27 Sponsors: AG1 & LMNT 00:50:36 Intersex Individuals, Castration 00:52:23 Female Sexual Behavior, Brain, Testosterone & Pheromones 00:57:58 Identify as Heterosexual or Homosexual, Difference in Hormone Levels? 01:00:42 Gender, Sexual Orientation & Hormones; Hormone Replacement Therapy 01:10:21 Aromatization; Steroid Hormones & Gene Expression 01:15:00 Kids & Changing Gender Identity 01:19:05 Sexual Behavior, Refractory Period & Male Brain, Tacr1 Cells 01:21:31 Sponsor: Function 01:23:19 Hypothalamus, Dopamine, Prolactin, Cabergoline, Libido, Dopamine 01:27:05 Brain Circuits, Aggression & Sexual Behavior 01:32:40 Refractory Period; Age, Testosterone & Libido 01:36:07 Tacr1 Cells in Females, Periaqueductal Gray & Innate Behaviors 01:40:00 Parenting Behaviors & Brain Circuits; Pet Dogs 01:43:12 Oxytocin, Pair Bonding, Vasopressin; Biological Redundancy 01:47:22 Libido, Melanocortin, Tacr1 Neurons; GLP-1 Agonists, Clinical Trials; Kisspeptin 01:56:43 Female Brain Changes, Menstrual Cycle, Pregnancy, Menopause; Estrogen; Men & Hormone Fluctuation? 02:04:10 Life Experience Male vs Female, Sex Recognition, Behaviors & Context 02:16:05 Pain Management; Endocrine Disrupters, Gender Identity 02:21:03 Future Projects 02:24:29 Zero-Cost Support, YouTube, Spotify & Apple Follow & Reviews, Sponsors, YouTube Feedback, Protocols Book, Social Media, Neural Network Newsletter Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices

Neurology Minute
Updates in Neuroinfectious Diseases - Part 6

Neurology Minute

Play Episode Listen Later Jul 28, 2025 3:15


In part six of this ten-part series, Dr. Paul Crane and Dr. Prashanth Ramachandran discuss findings from a recent systematic review on pneumococcal meningitis, including the role of corticosteroid, the importance of treatment timing, and emerging adjunctive therapies that may improve patient outcomes. Show reference:  https://academic.oup.com/braincomms/article/6/3/fcae131/7644484

MedEvidence! Truth Behind the Data

MedEvidence! Truth Behind the Data

Play Episode Listen Later Jul 28, 2025 10:38 Transcription Available


Send us a textCardiologist Dr. Michael Koren joins Kevin Geddings to talk about how we can learn a lot about medicine by knowing our history. The duo discuss how the history of healthcare, including smallpox inoculation in the 1800s, can inform us of the benefits of life-saving medicines like vaccines. They also talk about the history of obesity, the old city of St. Augustine, and how all of this relates to modern medicine.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Tech Lead Journal
#226 - Ex-Google Duplex Eng Lead on Disrupting $2B Clinical Trials with AI - Patrick Leung

Tech Lead Journal

Play Episode Listen Later Jul 28, 2025 54:27


Ever wondered how AI is being applied in the world of clinical trials where human lives are at stake?In this episode, Patrick Leung, CTO of Faro Health and former Google Duplex Engineering Lead, reveals how AI is transforming the clinical trial process — a process that can cost up to $2 billion per drug and take over 10 years to complete. Patrick reveals how Faro Health's AI systems generate complex clinical documentation in minutes instead of months in which hallucinations aren't acceptable, while navigating the strict regulatory requirements of the healthcare industry.Patrick also reflects on the evolution of AI technologies, the realities of large language models, and offers practical advice on how to thrive in the rapidly changing AI-driven era.Key topics discussed:The evolution of AI from image recognition and Google Duplex to LLMsHow Faro Health uses AI to transform clinical trial processThe challenges of applying AI in highly regulated industriesAI's potential to save time and millions in clinical trialsHow to tackle AI hallucinations and ensure high-quality outputsPatrick's thoughts on AGI and the future of AI beyond current capabilitiesThe viability and limitations of vibe codingStrategies and advice for individuals to thrive in the AI eraTimestamps:(00:00) Trailer & Intro(02:09) Career Turning Points(02:46) The Advancements of AI in the Past 10 Years(04:13) Non-LLM Types of AI(05:42) The Google Duplex(07:28) The Use of AI in Faro Health(09:44) Tackling AI Hallucination for Clinical Documents(12:25) Building the Evaluation Process on AI Results(14:28) AI as a Research Assistant(16:40) The Need of Building Custom AI Model(18:50) The Huge Impact of AI in Clinical Trials(21:15) The Regulations on Applying AI Technology(23:28) AI Success Stories in the Life Science Industry(25:16) The Possibility of AGI(28:36) The Path to AGI Using LLM(30:43) Actions People Should Take in the AI Era(35:48) AI Engineers and AI-Enabled Engineers(38:37) The Viability of Vibe Coding(41:03) Hiring AI Engineers(42:26) Important Engineer Attributes in the AI Era(44:23) Important Leader Attributes in the AI Era(46:59) The Room for Juniors in the AI Era(49:04) Inspirational Story of a Successful Junior(51:33) 3 Tech Lead Wisdom_____Patrick Leung's BioPatrick Leung is a Chief Technology Officer at Faro Health, a company at the forefront of optimizing clinical trial development through the use of artificial intelligence.In his role, he is instrumental in applying large language models and other AI technologies to enhance protocol design and outcomes for clinical trials. A native of New Zealand, Mr. Leung holds degrees in Computer Science and Finance.His career includes being a foundational member of an early e-commerce software company, where he played a key role in guiding the company from its initial stages to a successful initial public offering.Follow Patrick:LinkedIn – linkedin.com/in/puiwahTwitter – x.com/puiwahWebsite – farohealth.comLike this episode?Show notes & transcript: techleadjournal.dev/episodes/226.Follow @techleadjournal on LinkedIn, Twitter, and Instagram.Buy me a coffee or become a patron.

Surfing the Nash Tsunami
6.8.2 - Newsmaker: GLI President and CEO Larry Holden discusses Changes in Washington and How We Can Proceed

Surfing the Nash Tsunami

Play Episode Listen Later Jul 28, 2025 31:08


Send us a textGlobal Liver Institute President and CEO Larry Holden joins Roger Green to discuss recent Washington political and regulatory activities, their potential impact on the liver community, and ways we can respond.Larry starts by acknowledging that we are in for "dark times" under the current administration and describes some current government actions that are causing major setbacks, as well as others that have the potential to do so. Specifically, he details the challenges caused by budget cuts, reallocation of funds away from major universities, staff reductions and, along with them, a loss of expertise in technical areas where knowledge and experience are pivotal.Without minimizing these challenges, Larry proceeds to suggest actions that individuals and organizations can take to reduce losses to the greatest extent possible — and even create some "wins" — for people living with liver disease. He describes tactics for giving legislators something they value (mainly publicity and contacts) to build a relationship, gain access and create a sympathetic ear for liver community messages. The conversation itself shifts back and forth between some of the current challenges and the steps advocates can take to mitigate losses and, whenever possible, achieve "wins." Sometimes discouraging, sometimes educational, this is an essential conversation for all current and potential advocates for liver patients to hear.

OffScrip with Matthew Zachary
The Cancer Fun House: Michele Andrews

OffScrip with Matthew Zachary

Play Episode Listen Later Jul 22, 2025 41:39


Michelle Andrews built a career inside the pharma machine long before anyone knew what “DTC” meant. She helped launch Rituxan and watched Allegra commercials teach America how to ask for pills by name. Then she landed in the cancer fun house herself, stage 4 breast cancer, and learned exactly how hollow all the “journey” slide decks feel when you're the one circling the drain.We talk about what happens when the insider becomes the customer, why pill organizers and wheat field brochures still piss her off, and how she fired doctors who couldn't handle her will to live. You'll hear about the dawn of pharma advertising, the pre-Google advocacy hustle, and what she wants every brand team to finally admit about patient experience.If you've ever wondered who decided windsurfing was the best way to sell allergy meds—or what happens when you stop caring if you make people uncomfortable—listen up.RELATED LINKSMichelle Andrews on LinkedInTrinity Life Sciences – Strategic AdvisoryJade Magazine – Ticking Time Bombs ArticleNIHCM Foundation – Breast Cancer StoryFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Neurology Minute
Efficacy of Aerobic Exercise and Coaching on Physical Fitness in Neuromuscular Disease - Part 2

Neurology Minute

Play Episode Listen Later Jul 22, 2025 2:11


In the second episode of this two-part series, Dr. Justin Abbatemarco and Dr. Eric L. Voorn discuss how to integrate these coaching elements into practice to promote sustainable changes.  Show reference:  https://www.neurology.org/doi/10.1212/WNL.0000000000213781  https://www.sciencedirect.com/science/article/pii/S0960896625000458?via%3Dihub 

The MedTech Podcast
#86 Sepsis, Speed and Saving Lives with Dr. Rolland Carlson: Gene Signatures, Clinical Trials, and the Future of Infection Detection

The MedTech Podcast

Play Episode Listen Later Jul 22, 2025 29:52


Dr. Rolland “Rollie” Carlson, CEO of Immunexpress is a veteran of the molecular diagnostics space. With over 25 years of leadership across Abbott, WaferGen, Asuragen, and more, Rollie is now focused on solving one of healthcare's most urgent crises: Sepsis.In this episode, we explore why sepsis, despite causing more than 48 million deaths annually remains so poorly understood and misdiagnosed. Rollie breaks down why early detection is so difficult, how gene expression profiling can finally distinguish between infectious and non-infectious inflammation and the real-world barriers to clinical trial design, FDA approval and physician adoption. We also cover military use cases, the lack of gold standards in sepsis diagnostics and what needs to change in how hospitals are incentivised to tackle this conditionTimestamps:[00:00:26] Why Sepsis Remains Underdiagnosed Globally[00:01:42] What Sepsis Actually Is and Why It's So Deadly[00:03:14] Who's Most at Risk: Age, Immunity, and Beyond[00:04:25] Detecting Sepsis Through Gene Expression[00:05:39] Why Blood Cultures Aren't Enough Anymore[00:09:14] FDA Approval Without a Gold Standard: The Regulatory Maze[00:12:39] Sepsis Isn't Always Bacterial and Why That Matters[00:15:20] How Physicians Are Reacting to New Molecular Tools[00:17:35] Beyond Sepsis: Expansion Into Infectious Diseases[00:18:57] From Marine Biologist to Diagnostics PioneerGet in touch with Rollie - https://www.linkedin.com/in/rollie-carlson-ph-d-059074a/ Learn more about Immunexpress - https://immunexpress.com/ Get in touch with Karandeep Badwal - https://www.linkedin.com/in/karandeepbadwal/ Follow Karandeep on YouTube - https://www.youtube.com/@KarandeepBadwalSubscribe to the Podcast

The Incubator
#331 -

The Incubator

Play Episode Listen Later Jul 20, 2025 84:35


Send us a textIn this week's Journal Club, Ben and Daphna dive into several impactful neonatal studies shaping today's clinical decisions. The discussion opens with the MOCA Trial, exploring whether extending caffeine therapy in moderately preterm infants reduces hospital stays and improves outcomes. Despite reducing apnea episodes, the study highlights that extending caffeine treatment does not reduce time to discharge.Next, the team reviews a randomized trial on late permissive hypercapnia in mechanically ventilated preterm infants, showing that targeting slightly higher CO₂ levels can shorten invasive ventilation time without worsening long-term outcomes.Midway through the episode, we feature an EBNEO commentary with Dr. Kira McNellis on early full enteral nutrition with fortified milk in very preterm infants. She explains why fat-free mass is an important nutritional marker linked to neurodevelopment and why “negative” nutrition studies still matter for clinical practice.Other key papers include cumulative neonatal morbidities predicting long-term neurodevelopment, the long-term academic Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

The Incubator
#331 - [Journal Club Shorts] -

The Incubator

Play Episode Listen Later Jul 20, 2025 20:18


Send us a textEarly full enteral nutrition with fortified milk in very preterm infants: a randomized clinical trial.Salas AA, Gunawan E, Jeffcoat S, Nguyen K.Am J Clin Nutr. 2025 May;121(5):1117-1123. doi: 10.1016/j.ajcnut.2025.02.019. Epub 2025 Feb 21.PMID: 39986385 Clinical Trial.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

The Incubator
#331 - [Journal Club Shorts] -

The Incubator

Play Episode Listen Later Jul 20, 2025 10:38


Send us a textExtended Caffeine for Apnea in Moderately Preterm Infants: The MoCHA Randomized Clinical Trial.Carlo WA, Eichenwald EC, Carper BA, Bell EF, Keszler M, Patel RM, Sánchez PJ, Goldberg RN, D'Angio CT, Van Meurs KP, Hibbs AM, Ambalavanan N, Cosby SS, Newman NS, Vohr BR, Walsh MC, Das A, Ohls RK, Fuller J, Rysavy MA, Ghavam S, Brion LP, Puopolo KM, Moore R, Baack ML, Colaizy TT, Baserga M, Osman AF, Merhar SL, Poindexter BB, DeMauro SB, Kumar V, Cotten CM; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network.JAMA. 2025 Jun 24;333(24):2154-2163. doi: 10.1001/jama.2025.5791.PMID: 40294395 Clinical Trial.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

The Incubator
#331 - [Journal Club Shorts] -

The Incubator

Play Episode Listen Later Jul 20, 2025 14:32


Send us a textLate Permissive Hypercapnia for Mechanically Ventilated Preterm Infants: A Randomized Trial.Travers CP, Gentle SJ, Shukla VV, Aban I, Yee AJ, Armstead KM, Benz RL, Laney D, Ambalavanan N, Carlo WA.Pediatr Pulmonol. 2025 Jun;60(6):e71165. doi: 10.1002/ppul.71165.PMID: 40525736 Free PMC article. Clinical Trial.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Neurology Minute
Efficacy of Aerobic Exercise and Coaching on Physical Fitness in Neuromuscular Disease - Part 1

Neurology Minute

Play Episode Listen Later Jul 17, 2025 2:10


In part one of this two-part series, Dr. Justin Abbatemarco and Dr. Eric L. Voorn discuss how exercise remains essential for people with neuromuscular disorders, even amid limited pharmaceutical options and safety concerns.  Show reference:  https://www.neurology.org/doi/10.1212/WNL.0000000000213781 https://www.sciencedirect.com/science/article/pii/S0960896625000458?via%3Dihub

OffScrip with Matthew Zachary
D.A.M.M. Good Trouble: Ann Marie Morse

OffScrip with Matthew Zachary

Play Episode Listen Later Jul 15, 2025 43:12


Dr. Anne Marie Morse walks into the studio like a one-woman Jersey Broadway show and leaves behind the best damn TED Talk you've never heard. She's a neurologist, sleep medicine doc, narcolepsy expert, founder of D.A.M.M. Good Sleep, and full-time myth buster in a white coat. We talk about why sleep isn't a luxury, why your mattress does matter, and how melatonin is the new Flintstones vitamin with a marketing budget. We unpack the BS around sleep hygiene, blow up the medical gaslighting around “disorders,” and dig into how a former aspiring butterfly became one of the loudest voices for patient-centered science. Also: naps, kids, burnout, CPAPs, co-sleeping, airport pods, the DeLorean, and Carl Sagan. If you think you're getting by on five hours of sleep and vibes, you're not. This episode will make you want to take a nap—and then call your doctor.RELATED LINKSdammgoodsleep.com: https://www.dammgoodsleep.comLinkedIn: https://www.linkedin.com/in/anne-marie-morse-753b2821/Instagram: https://www.instagram.com/dammgoodsleepDocWire News Author Page: https://www.docwirenews.com/author/anne-marie-morseSleep Review Interview: https://sleepreviewmag.com/practice-management/marketing/word-of-mouth/sleep-advocacy-anne-marie-morse/Geisinger Bio: https://providers.geisinger.org/provider/anne-marie-morse/756868SWHR Profile: https://swhr.org/team/anne-marie-morse-do-faasm/FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.